STAA Quote, Financials, Valuation and Earnings

OrthoPediatrics has a net margin of -127.29% compared to Staar Surgical's net margin of -20.34%. Staar Surgical's return on equity of -17.97% beat OrthoPediatrics's return on equity of -11.21%.

Staar Surgical has a consensus price target of $19.20, signalling upside risk potential of 12.35%. On the other hand OrthoPediatrics has an analysts' consensus of $36.71 which suggests that it could grow by 62.09%. Given that OrthoPediatrics has higher upside potential than Staar Surgical, analysts believe OrthoPediatrics is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.582, which suggesting that the stock is 41.753% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.802%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $42.6M, which are smaller than OrthoPediatrics quarterly revenues of $52.4M. Staar Surgical's net income of -$54.2M is lower than OrthoPediatrics's net income of -$10.7M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 3.03x versus 2.47x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -127.29% compared to Staar Surgical's net margin of -391.35%. Staar Surgical's return on equity of -17.97% beat Innovative Eyewear's return on equity of -97.69%.

Staar Surgical has a consensus price target of $19.20, signalling upside risk potential of 12.35%. On the other hand Innovative Eyewear has an analysts' consensus of $7.00 which suggests that it could grow by 228.64%. Given that Innovative Eyewear has higher upside potential than Staar Surgical, analysts believe Innovative Eyewear is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.582, which suggesting that the stock is 41.753% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $42.6M, which are larger than Innovative Eyewear quarterly revenues of $454.5K. Staar Surgical's net income of -$54.2M is lower than Innovative Eyewear's net income of -$1.8M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 3.03x versus 2.40x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -127.29% compared to Staar Surgical's net margin of -45.89%. Staar Surgical's return on equity of -17.97% beat Masimo's return on equity of -39.91%.

Staar Surgical has a consensus price target of $19.20, signalling upside risk potential of 12.35%. On the other hand Masimo has an analysts' consensus of $184.37 which suggests that it could grow by 16.43%. Given that Masimo has higher upside potential than Staar Surgical, analysts believe Masimo is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.582, which suggesting that the stock is 41.753% less volatile than S&P 500. In comparison Masimo has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.716%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $42.6M, which are smaller than Masimo quarterly revenues of $372M. Staar Surgical's net income of -$54.2M is higher than Masimo's net income of -$170.7M. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 3.03x versus 4.35x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -127.29% compared to Staar Surgical's net margin of -25.37%. Staar Surgical's return on equity of -17.97% beat NexGel's return on equity of -59.55%.

Staar Surgical has a consensus price target of $19.20, signalling upside risk potential of 12.35%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 151.05%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

Staar Surgical has a beta of 0.582, which suggesting that the stock is 41.753% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Staar Surgical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Staar Surgical pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

Staar Surgical quarterly revenues are $42.6M, which are larger than NexGel quarterly revenues of $2.8M. Staar Surgical's net income of -$54.2M is lower than NexGel's net income of -$712K. Notably, Staar Surgical's price-to-earnings ratio is 49.73x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Staar Surgical is 3.03x versus 1.62x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.